Press Releases on September 17, 2018 - EIN Presswire - Press Release Distribution Service

Published on September 17, 2018 - 12:01 GMT

Human medicines European public assessment report (EPAR): Pravafenix, fenofibrate,pravastatin, Dyslipidemias, Date of ...

The most common side effects with Pravafenix (seen in between 1 and 10 patients in 100) are abdominal distension (bloating), abdominal pain (stomach ache), constipation, diarrhoea, dry mouth, dyspepsia (heartburn), eructation (belching), flatulence (gas), …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 17, 2018 - 12:01 GMT

Human medicines European public assessment report (EPAR): Vizamyl, flutemetamol (18F), Radionuclide Imaging;Alzheimer Disease, ...

The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Vizamyl’s benefits are greater than its risks and recommended that it be approved for use in the EU. The Committee noted that PET scans with Vizamyl have a high sensitivity and …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 17, 2018 - 12:01 GMT

Human medicines European public assessment report (EPAR): Vizamyl, flutemetamol (18F), Radionuclide Imaging;Alzheimer Disease, ...

The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Vizamyl’s benefits are greater than its risks and recommended that it be approved for use in the EU. The Committee noted that PET scans with Vizamyl have a high sensitivity and …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 17, 2018 - 12:01 GMT

Human medicines European public assessment report (EPAR): Zubsolv, buprenorphine,naloxone, Opioid-Related Disorders, Date of ...

Substitution treatment for opioid drug dependence, within a framework of medical, social and psychological treatment. The intention of the naloxone component is to deter intravenous misuse. Treatment is intended for use in adults and adolescents over 15 …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 17, 2018 - 12:01 GMT

Human medicines European public assessment report (EPAR): Zubsolv, buprenorphine,naloxone, Opioid-Related Disorders, Date of ...

Substitution treatment for opioid drug dependence, within a framework of medical, social and psychological treatment. The intention of the naloxone component is to deter intravenous misuse. Treatment is intended for use in adults and adolescents over 15 …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 17, 2018 - 12:01 GMT

Opinion/decision on a Paediatric investigation plan (PIP): Fenfluramine hydrochloride, decision type: , therapeutic area: , PIP ...

For the United Kingdom, as of 1 January 2021, European Union law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland / NI.

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 17, 2018 - 12:01 GMT

Opinion/decision on a Paediatric investigation plan (PIP): Otezla,apremilast, decision type: , therapeutic area: , PIP number: P/...

For the United Kingdom, as of 1 January 2021, European Union law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland / NI.

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 17, 2018 - 12:01 GMT

Opinion/decision on a Paediatric investigation plan (PIP): Atectura Breezhaler,Indacaterol (acetate),Mometasone furoate, decision ...

For the United Kingdom, as of 1 January 2021, European Union law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland / NI.

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 17, 2018 - 12:01 GMT

Playa Hotels & Resorts and Hilton Announce Strategic Alliance and Future Conversion of Two Initial All-inclusive Resorts

FAIRFAX, Va. and MCLEAN, Va., Sept. 17, 2018 (GLOBE NEWSWIRE) -- Playa Hotels & Resorts N.V. (NASDAQ: PLYA) and Hilton (NYSE: HLT) today announced plans to leverage Playa Hotels & Resorts’ industry-leading, all-inclusive expertise with Hilton’s …

Distribution channels: Travel & Tourism Industry ...